Published in Cancer Res on March 01, 2002
Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci (2010) 1.29
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin. PLoS Pathog (2009) 1.10
Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem (2011) 0.99
Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol (2005) 0.97
Heat shock protein 60 acts as a receptor for the Listeria adhesion protein in Caco-2 cells. Infect Immun (2004) 0.96
Heat shock proteins in multiple myeloma. Oncotarget (2014) 0.95
The odyssey of Hsp60 from tumor cells to other destinations includes plasma membrane-associated stages and Golgi and exosomal protein-trafficking modalities. PLoS One (2012) 0.95
Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity. Biochem J (2005) 0.92
A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis. Mol Cell Proteomics (2014) 0.92
Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol (2011) 0.91
Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Sci (2008) 0.87
Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. Cancer Sci (2009) 0.87
Insulin Dependant Gene Expression of Heat Shock Protein 60 in H4IIE Hepatoma Cells. Int J Clin Exp Med (2008) 0.80
The potential role of heat shock proteins in acute spinal cord injury. Eur Spine J (2014) 0.80
A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol (2013) 0.79
Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment. Mol Cell Ther (2014) 0.79
Ribozyme-mediated gene knock down strategy to dissect the consequences of PDGF stimulation in vascular smooth muscle cells. BMC Res Notes (2012) 0.78
Protein-based identification of quantitative trait loci associated with malignant transformation in two HER2+ cellular models of breast cancer. Proteome Sci (2012) 0.78
PRL-3 mediates the protein maturation of ULBP2 by regulating the tyrosine phosphorylation of HSP60. J Immunol (2015) 0.76
Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors. PLoS One (2014) 0.76
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem (2006) 2.23
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A (2005) 2.17
Increasing survival of ischemic tissue by targeting CD47. Circ Res (2007) 2.16
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res (2010) 1.91
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood (2007) 1.73
Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood (2006) 1.56
Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A (2005) 1.55
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med (2009) 1.47
Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int (2004) 1.44
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res (2006) 1.43
Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem (2007) 1.41
Arginine-induced germ tube formation in Candida albicans is essential for escape from murine macrophage line RAW 264.7. Infect Immun (2009) 1.38
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem (2008) 1.34
The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal (2006) 1.32
Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res (2003) 1.32
Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res (2008) 1.30
Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol (2002) 1.29
Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res (2007) 1.28
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem (2010) 1.27
CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy (2012) 1.27
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol (2008) 1.26
Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A (2007) 1.26
Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol (2007) 1.25
Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy. Cell Biosci (2014) 1.24
Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg (2008) 1.24
Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol (2009) 1.23
Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res (2008) 1.23
Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem (2006) 1.22
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem (2004) 1.19
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion. J Biol Chem (2002) 1.18
PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas (2008) 1.17
Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide (2008) 1.14
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol (2005) 1.14
Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann Surg (2008) 1.13
Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin. J Biol Chem (2003) 1.13
Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep (2013) 1.12
Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res (2008) 1.12
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery (2008) 1.12
IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med (2011) 1.11
TSG-6 binds via its CUB_C domain to the cell-binding domain of fibronectin and increases fibronectin matrix assembly. Matrix Biol (2007) 1.11
Nitric oxide in wound-healing. Microsurgery (2005) 1.10
Heme oxygenase in Candida albicans is regulated by hemoglobin and is necessary for metabolism of exogenous heme and hemoglobin to alpha-biliverdin. J Biol Chem (2003) 1.09
Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine (2007) 1.08
Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res (2003) 1.07
Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds. Nat Commun (2012) 1.06
CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol (2008) 1.05
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg (2009) 1.05
Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep (2013) 1.05
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res (2010) 1.01
Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem (2011) 0.99
Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells. J Cell Sci (2006) 0.99
Hemoglobin regulates expression of an activator of mating-type locus alpha genes in Candida albicans. Eukaryot Cell (2004) 0.99
Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol (2010) 0.97
A novel role of the chromokinesin Kif4A in DNA damage response. Cell Cycle (2008) 0.97
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther (2002) 0.96
Silencing of directional migration in roundabout4 knockdown endothelial cells. BMC Cell Biol (2008) 0.96
Hydrogen sulfide is an endogenous potentiator of T cell activation. J Biol Chem (2011) 0.96
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med (2013) 0.95
Sensing the host environment: recognition of hemoglobin by the pathogenic yeast Candida albicans. Arch Biochem Biophys (2004) 0.95
Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res (2010) 0.95
Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem (2009) 0.95
The N-terminal module of thrombospondin-1 interacts with the link domain of TSG-6 and enhances its covalent association with the heavy chains of inter-alpha-trypsin inhibitor. J Biol Chem (2005) 0.95
Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies. Proc Natl Acad Sci U S A (2012) 0.94
Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol (2011) 0.94
Evolutionary aspects of urea utilization by fungi. FEMS Yeast Res (2010) 0.93
Novel integrin antagonists derived from thrombospondins. Curr Pharm Des (2005) 0.93
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther (2002) 0.93
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia (2008) 0.92
Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine (2005) 0.91
Candida albicans heme oxygenase and its product CO contribute to pathogenesis of candidemia and alter systemic chemokine and cytokine expression. Free Radic Biol Med (2010) 0.91
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. PLoS One (2010) 0.91
CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit Rev Biochem Mol Biol (2015) 0.90
Optimization of gene expression in nonactivated circulating lymphocytes. Mol Ther (2003) 0.90
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer (2009) 0.89
Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev (2009) 0.89
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets (2012) 0.89
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling. Curr Drug Targets (2008) 0.88
Calcium indirectly regulates immunochemical reactivity and functional activities of the N-domain of thrombospondin-1. Matrix Biol (2007) 0.88
Urea amidolyase (DUR1,2) contributes to virulence and kidney pathogenesis of Candida albicans. PLoS One (2012) 0.87
Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol (2013) 0.87
Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management. Am J Physiol Renal Physiol (2012) 0.87
Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol (2004) 0.87
Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis. PLoS One (2012) 0.87
Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation. J Genet Syndr Gene Ther (2011) 0.86
Comprehensive characterization of heat shock protein 27 phosphorylation in human endothelial cells stimulated by the microbial dithiole thiolutin. J Proteome Res (2008) 0.85
CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle (2011) 0.84
sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration. Arch Biochem Biophys (2011) 0.84
Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol (2007) 0.84